Last updated 2026-06-18
- Raised $1M Seed round led by Integra Holdings, Dec 2013
Total raised
$1.0M
Last: Undisclosed Round 2014-01
Stage
Seed
Founded
2014
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye. This platform technology can also be used for front-of-the-eye treatments. OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES. OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.
Funding history · 1 round · $1.0M total
2013-12
Seed
$1.0M
★ Integra Holdings★ XLVision Sciences★ BIOLIGHT Life Sciences★ Kremer & Lieberman groups
Q&A
- What is OphRx's primary focus?
- OphRx is developing noninvasive drug-delivery technology for ocular use, specifically eye drops that utilize lyotropic liquid crystals as an alternative to current delivery methods for treating eye diseases.
- What product candidates is OphRx currently developing?
- OphRx is in the preclinical stage of developing two product candidates: OPH-101, a topical treatment for wet AMD, and OPH-100, a treatment for Dry Eye Syndrome (DES).
- When was OphRx founded?
- OphRx was founded in January 2014.
- What is OphRx's current funding stage?
- OphRx is currently in the Seed funding stage.
- Who are the key investors in OphRx?
- In January 2014, OphRx received funding from BIOLIGHT Life Sciences and Kremer & Lieberman groups.
- What is the total amount of funding OphRx has raised to date?
- OphRx has raised a total of $1,000,000 USD.
- Who is the CEO of OphRx?
- Sharon Bakalash is the CEO of OphRx.
- What is OphRx's relationship with BioLight Life Sciences Investments?
- OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
healthcare-providersclinicsdoctorstopical-treatmentnanotechnologypharmaceuticalsophthalmologyeye-diseasesnon-invasivepharma-companiesglaucomamedical-technologiesdrug-delivery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bio-light.co.il/ophrx-2/ |
|---|---|
| linkedin.com/company/54362622 |
Identifiers & details
| Founded | 2014-1 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Web history (Wayback)
| Domain | bio-light.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515226702 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-03-15 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 3 — people (2), annual_report (1) |
| Registered address | דרך אבא הלל 12 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2026-03-25 | עדכון דירקטורים-הסרת דירקטור |
| 2026-03-25 | דו~ח שנתי |
| 2026-03-25 | עדכון דירקטורים-הוספת דירקטור |